Skip Nav Destination
Issues
1 July 2020
-
Cover Image
Cover Image
MicroRNA (miRNA) dysregulation in pancreatic ductal adenocarcinoma (PDA) has been reported but not previously profiled during PDA tumorigenesis. Chu and colleagues (in a study beginning on page 569) identified miRNA-21 (miR-21) overexpression in pre-malignant and PDA lesions and demonstrated regulation of pro-tumorigenic effector pathways including MAPK, mTOR and actin cytoskeleton pathways downstream of mutant KRAS. Early systemic miR-21 inhibition in vivo completely intercepted premalignant progression in the early pancreatic intraepithelial neoplasia (PanIN) stage. The cover art demonstrates miRNA-21 expression in PDA using a fluorescence in situ hybridization assay. Expression of miR-21 is concentrated in ductal epithelial cells and becomes increasingly expressed with neoplastic progression from PanINs to PDA (miR-21 expression in epithelial ducts in green and DAPI in the nucleus in blue). miR-21 may be useful for identifying and intercepting developing PDA and other KRAS-driven cancers. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Research Articles
Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development
Nina J. Chu; Robert A. Anders; Elana J. Fertig; Minwei Cao; Alexander C. Hopkins; Bridget P. Keenan; Aleksandra Popovic; Todd D. Armstrong; Elizabeth M. Jaffee; Jacquelyn W. Zimmerman
Reasons for Not Attending Cervical Cancer Screening and Associated Factors in Rural Ethiopia
Muluken Gizaw; Brhanu Teka; Friederike Ruddies; Konjit Kassahun; Dawit Worku; Alemayehu Worku; Andreas Wienke; Rafael Mikolajczyk; Ahmedin Jemal; Andreas M. Kaufmann; Tamrat Abebe; Adamu Addissie; Eva Johanna Kantelhardt
Author Choice
Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer
Carol J. Fabian; Seema A. Khan; Judy E. Garber; William C. Dooley; Lisa D. Yee; Jennifer R. Klemp; Jennifer L. Nydegger; Kandy R. Powers; Amy L. Kreutzjans; Carola M. Zalles; Trina Metheny; Teresa A. Phillips; Jinxiang Hu; Devin C. Koestler; Prabhakar Chalise; Nanda Kumar Yellapu; Cheryl Jernigan; Brian K. Petroff; Stephen D. Hursting; Bruce F. Kimler
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.